Don’t Sell Terveystalo Oyj (HEL:TTALO) Before You Read This

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we’ll show how Terveystalo Oyj’s (HEL:TTALO) P/E ratio could help you assess the value on offer. Looking at earnings over the last twelve months, Terveystalo Oyj has a P/E ratio of 22.22. In other words, at today’s prices, investors are paying €22.22 for every €1 in prior year profit.

View our latest analysis for Terveystalo Oyj

How Do You Calculate A P/E Ratio?

The formula for price to earnings is:

Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Or for Terveystalo Oyj:

P/E of 22.22 = €9.460 ÷ €0.426 (Based on the trailing twelve months to December 2019.)

(Note: the above calculation results may not be precise due to rounding.)

Is A High Price-to-Earnings Ratio Good?

A higher P/E ratio means that buyers have to pay a higher price for each €1 the company has earned over the last year. That isn’t a good or a bad thing on its own, but a high P/E means that buyers have a higher opinion of the business’s prospects, relative to stocks with a lower P/E.

How Does Terveystalo Oyj’s P/E Ratio Compare To Its Peers?

We can get an indication of market expectations by looking at the P/E ratio. You can see in the image below that the average P/E (21.1) for companies in the healthcare industry is roughly the same as Terveystalo Oyj’s P/E.

HLSE:TTALO Price Estimation Relative to Market May 1st 2020
HLSE:TTALO Price Estimation Relative to Market May 1st 2020

Terveystalo Oyj’s P/E tells us that market participants think its prospects are roughly in line with its industry. If the company has better than average prospects, then the market might be underestimating it. I would further inform my view by checking insider buying and selling., among other things.

How Growth Rates Impact P/E Ratios

Generally speaking the rate of earnings growth has a profound impact on a company’s P/E multiple. That’s because companies that grow earnings per share quickly will rapidly increase the ‘E’ in the equation. That means even if the current P/E is high, it will reduce over time if the share price stays flat. Then, a lower P/E should attract more buyers, pushing the share price up.

Terveystalo Oyj’s earnings per share fell by 21% in the last twelve months. But EPS is up 58% over the last 3 years.

Remember: P/E Ratios Don’t Consider The Balance Sheet

The ‘Price’ in P/E reflects the market capitalization of the company. That means it doesn’t take debt or cash into account. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

Spending on growth might be good or bad a few years later, but the point is that the P/E ratio does not account for the option (or lack thereof).

Terveystalo Oyj’s Balance Sheet

Terveystalo Oyj has net debt equal to 28% of its market cap. You’d want to be aware of this fact, but it doesn’t bother us.

The Verdict On Terveystalo Oyj’s P/E Ratio

Terveystalo Oyj trades on a P/E ratio of 22.2, which is above its market average of 18.6. With some debt but no EPS growth last year, the market has high expectations of future profits.

When the market is wrong about a stock, it gives savvy investors an opportunity. People often underestimate remarkable growth — so investors can make money when fast growth is not fully appreciated. So this free visual report on analyst forecasts could hold the key to an excellent investment decision.

But note: Terveystalo Oyj may not be the best stock to buy. So take a peek at this free list of interesting companies with strong recent earnings growth (and a P/E ratio below 20).

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.